Related Experiment Video
Updated: Jun 17, 2026

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
Effect of spironolactone on urinary protein excretion in patients with chronic kidney disease
Erkan Sengul1, Tayfun Sahin, Erce Sevin
1Department of Nephrology, Faculty of Medicine, University of Kocaeli, Kocaeli, Turkey. dr.erkansengul@hotmail.com
Insights
Spironolactone significantly reduced proteinuria in chronic kidney disease patients. This treatment may help slow kidney disease progression, but requires careful monitoring for hyperkalemia.
Area of Science:
- Nephrology
- Pharmacology
Background:
- Chronic kidney disease (CKD) is a progressive condition often managed with renin-angiotensin system inhibitors.
- Proteinuria is a key marker of CKD progression and cardiovascular risk.
Purpose of the Study:
- To evaluate the antiproteinuric effect of spironolactone in CKD patients already treated with ACE inhibitors and/or ARBs.
- To assess the impact of spironolactone on blood pressure and serum potassium levels.
Main Methods:
- A study involving 33 CKD patients with proteinuria.
- Spironolactone (25 mg/d) was added to existing ACE inhibitor/ARB therapy for eight weeks.
- Urinary protein excretion and biochemical parameters were measured before and after treatment.
Main Results:
- Spironolactone significantly decreased proteinuria by 47.9% (p < 0.001).
- Significant reductions in systolic and diastolic blood pressure were observed.
- Serum potassium levels increased significantly, indicating a risk of hyperkalemia.
Conclusions:
- Spironolactone demonstrates a significant antiproteinuric effect in CKD patients on ACE inhibitors/ARBs.
- This suggests spironolactone may be a valuable strategy for slowing CKD progression.
- Close monitoring of serum potassium is crucial due to the risk of hyperkalemia.
Aim:
To investigate antiproteinuric effect of spironolactone in patients with chronic kidney disease (CKD) treated with angiotensin-converting enzyme (ACE) inhibitors and/or angiotensin II type 1 receptor blockers (ARBs).
Methods:
This study was performed in 33 CKD patients with proteinuria. 24 h urinary protein excretion and biochemical parameters were obtained before the therapy. Then, spironolactone (25 mg/d) was added to the therapy. The antiproteinuric effect of spironolactone was examined for eight weeks.
Results:
At eight weeks, there was a significant decrease in proteinuria (p < 0.001, 47.9% decrease). Systolic and diastolic blood pressures were significantly decreased (p < 0.004, p < 0.001, respectively). However, no correlation was detected between the reductions in systolic and diastolic BP and the reduction in proteinuria (p = 0.464, p = 0.239, respectively). Serum potassium level increased significantly (p < 0.001).
Conclusions:
Our study suggests that spironolactone significantly reduces urinary protein excretion. This strategy may be useful to slow the progression of CKD. However, hyperkalemia is the most important side effect of treatment, and it is necessary to monitor potassium level. Further studies are needed to determine the efficacy of spironolactone on proteinuria.
Related Concept Videos
Nephrotic Syndrome II : Assessment and Medical Management
Antihypertensive Drugs: Potassium-Sparing Diuretics
Chronic Kidney Disease III: Interprofessional Care
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Antihypertensive Drugs: Action of Diuretics
Renal Drug Excretion: Tubular Reabsorption
